Skip to Content

New Drug Approvals Archive - October 2017

See also: New Indications and Dosage Forms for October 2017

October 2017

Ascor (ascorbic acid) Injection

Date of Approval: October 2, 2017
Company: McGuff Pharmaceuticals, Inc.
Treatment for: Scurvy

Ascor (ascorbic acid) is an intravenous vitamin C formulation indicated for the short term treatment of scurvy.

Zilretta (triamcinolone acetonide) Sustained-Release Intra-Articular Injection

Date of Approval: October 6, 2017
Company: Flexion Therapeutics, Inc.
Treatment for: Osteoarthritis

Zilretta (triamcinolone acetonide extended-release injectable suspension) is a corticosteroid intra-articular injection indicated for the management of osteoarthritis pain of the knee.

Yescarta (axicabtagene ciloleucel) Suspension for Intravenous Infusion - formerly KTE-C19

Date of Approval: October 18, 2017
Company: Kite Pharma, Inc.
Treatment for: Large B-Cell Lymphoma

Yescarta (axicabtagene ciloleucel) is a chimeric antigen receptor T cell (CAR T) therapy for the treatment of adults patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

CAR T therapy involves the engineering of a patient's T cells to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The T cells are then redirected to kill the cancer cells. CAR T therapy is manufactured specifically for each individual patient and is considered a breakthrough in hematologic cancer treatment.

Shingrix (zoster vaccine recombinant, adjuvanted) Injection

Date of Approval: October 20, 2017
Company: GlaxoSmithKline
Treatment for: Herpes Zoster -- Prophylaxis

Shingrix (zoster vaccine recombinant, adjuvanted) is a non-live, recombinant subunit vaccine for the prevention of herpes zoster (shingles) in adults aged 50 years and older.

Calquence (acalabrutinib) Capsules

Date of Approval: October 31, 2017
Company: AstraZeneca
Treatment for: Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia

Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.